For example, it is a marker of aggressive disease for certain subsets of T-cell non-Hodgkin lymphomas/leukemias, with expression of CD26 on T-lymphoblastic lymphomas/acute lymphoblastic leukemia cells being associated with a worse outcome compared with CD26-negative tumors [9]. This evidence concerns the gene DPP4 and T-lymphoblastic lymphoma.